title: Next-generation sequencing: application in liver cancer-past, present and future?
abstract: Hepatocellular Carcinoma (HCC) is the third most deadly malignancy worldwide characterized by phenotypic and molecular heterogeneity. In the past two decades, advances in genomic analyses have formed a comprehensive understanding of different underlying pathobiological layers resulting in hepatocarcinogenesis. More recently, improvements of sophisticated next-generation sequencing (NGS) technologies have enabled complete and cost-efficient analyses of cancer genomes at a single nucleotide resolution and advanced into valuable tools in translational medicine. Although the use of NGS in human liver cancer is still in its infancy, great promise rests in the systematic integration of different molecular analyses obtained by these methodologies, i.e., genomics, transcriptomics and epigenomics. This strategy is likely to be helpful in identifying relevant and recurrent pathophysiological hallmarks thereby elucidating our limited understanding of liver cancer. Beside tumor heterogeneity, progress in translational oncology is challenged by the amount of biological information and considerable "noise" in the data obtained from different NGS platforms. Nevertheless, the following review aims to provide an overview of the current status of next-generation approaches in liver cancer, and outline the prospects of these technologies in diagnosis, patient classification, and prediction of outcome. Further, the potential of NGS to identify novel applications for concept clinical trials and to accelerate the development of new cancer therapies will be summarized.
authors.affiliation: Department of Medicine I, Johannes Gutenberg University, Langenbeckstrasse 1, Mainz 55131, Germany ; Laboratory of Experimental Carcinogenesis, NCI/CCR, NIH, Bethesda, Maryland 20892, USA.
authors.forename: Jens U
authors.initials: JU
authors.lastname: Marquardt
authors.forename: Jesper B
authors.initials: JB
authors.lastname: Andersen
keywords: Hepatocellular carcinoma (HCC); Next-generation sequencing (NGS); integrative genomics; personalized medicine